Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Summary of Consolidated Financial Results for the Six Months Ended March 31, 2020 (Based on Japanese GAAP)

May 8, 2020

Company name:	Fuji Pharma Co., Ltd.	
Stock exchange listing:	Tokyo	
Stock code:	4554 URL http://www.fujipharma.jj	2
Representative:	President & CEO	Takayuki Iwai
	Director, Executive Corporate	
Inquiries:	Officer, General Manager, Corporate	Toyoyuki Kamide TEL 03-3556-3344
	Business Management Department	
Scheduled date to file Q	Quarterly Securities Report:	May 11, 2020
Scheduled date to comm	nence dividend payments:	June 1, 2020
Preparation of supplement	entary material on quarterly financial results:	Yes
Holding of quarterly fir	ancial results meeting:	Yes (for institutional investors and analysts)

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the six months ended March 31, 2020 (from October 1, 2019 to March 31, 2020)

(1) Consolidated operating results (cumulative)						es indica	ate year-on-year c	hanges
	Net sales	Net sales Operating profit		ofit	Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six months ended March 31, 2020	16,905	(8.5)	1,735	(29.7)	1,610	(35.6)	310	(81.7)
Six months ended March 31, 2019	18,483	2.9	2,467	8.4	2,501	6.0	1,695	(2.7)

	Earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended March 31, 2020	9.98	-
Six months ended March 31, 2019	56.66	-

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of March 31, 2020	58,162	39,262	67.5
As of September 30, 2019	60,737	39,363	64.8

2. Cash dividends

		Annual dividends per share						
	1st quarter-end	1st quarter-end 2nd quarter-end 3rd quarter-end Fiscal year-end Total						
	Yen	Yen	Yen	Yen	Yen			
Year ended September 30, 2019	-	14.00	-	15.00	29.00			
Year ending September 30, 2020	-	14.00						
Year ending September 30, 2020 (Forecast)			_	15.00	29.00			

3. Forecast of consolidated financial results for the year ending September 30, 2020 (from October 1, 2019 to September 30, 2020)

Percentages indicate year-on-year changes

	Net sales		Operating profit Or		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	33,830	(6.8)	2,571	(38.4)	2,501	(40.0)	492	(83.3)	15.78

4. Notes				
(1) Changes in significant subsidiaries during the			No	
(changes in specified subsidiaries resulting in	n the change in scope of co	onsolidation):	110	
(2) Application of special accounting methods for	or preparing quarterly cons	solidated financial statements:	No	
(3) Changes in accounting policies, changes in a	ccounting estimates, and r	estatement of prior period finan	cial stateme	ents
Changes in accounting policies due to revis	ions to accounting standar	ds and other regulations:	No	
Changes in accounting policies due to other	reasons:		No	
Changes in accounting estimates:			No	
Restatement of prior period financial staten	nents:		No	
(4) Number of issued shares (common shares)				
Total number of issued shares at the end of	the period (including treas	sury shares)		
As of March 31, 2020	31,253,800 shares	As of September 30, 2019	1	31,253,800 shares
Number of treasury shares at the end of the	period			
As of March 31, 2020	95,260 shares	As of September 30, 2019	1	101,726 shares

Α	Average number of shares during the period (cumulative from the beginning of the fiscal year)					
	Six months ended March 31, 202031,156,216 sharesSix months ended March 31, 201929,928,566 shares					

Quarterly consolidated financial statements Consolidated balance sheets

		(Millions of yen
	As of September 30, 2019	As of March 31, 2020
Assets		
Current assets		
Cash and deposits	8,494	6,04
Notes and accounts receivable - trade	12,944	12,87
Merchandise and finished goods	3,437	3,62
Work in process	2,539	2,62
Raw materials and supplies	4,735	5,65
Accounts receivable - other	43	5
Other	1,724	87
Allowance for doubtful accounts	(0)	(
Total current assets	33,919	31,74
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	5,117	4,90
Machinery, equipment and vehicles, net	1,646	1,68
Land	919	89
Leased assets, net	2,318	2,00
Construction in progress	1,484	2,57
Other, net	232	22
Total property, plant and equipment	11,718	12,29
Intangible assets		
Goodwill	1,494	1,27
Other	1,805	1,76
Total intangible assets	3,300	3,04
Investments and other assets		
Investment securities	7,342	6,63
Long-term advance payments	2,308	2,30
Deferred tax assets	1,288	1,30
Other	858	82
Total investments and other assets	11,798	11,07
Total non-current assets	26,817	26,42
Total assets	60,737	58,16

		(Millions of yea)
	As of September 30, 2019	As of March 31, 2020
Liabilities		
Current liabilities		
Notes and accounts payable - trade	4,813	6,000
Current portion of long-term borrowings	2,840	840
Lease obligations	530	502
Income taxes payable	492	270
Provision for bonuses	856	417
Provision for bonuses for directors (and other officers)	7	2
Provision for sales returns	22	25
Other	2,448	2,177
Total current liabilities	12,012	10,237
Non-current liabilities		
Long-term borrowings	5,530	5,110
Lease obligations	2,014	1,721
Retirement benefit liability	1,396	1,432
Other	418	399
Total non-current liabilities	9,360	8,663
Total liabilities	21,373	18,900
Net assets		
Shareholders' equity		
Share capital	3,799	3,799
Capital surplus	5,841	5,841
Retained earnings	29,243	29,086
Treasury shares	(78)	(68
Total shareholders' equity	38,804	38,657
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(340)	(20
Foreign currency translation adjustment	896	608
Remeasurements of defined benefit plans	(0)	13
Total accumulated other comprehensive income	556	601
Non-controlling interests	2	2
Total net assets	39,363	39,262
	60,737	58,162

Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)

Consolidated statements of income (cumulative)

		(Millions of yen)
	Six months ended	Six months ended
	March 31, 2019	March 31, 2020
Net sales	18,483	16,905
Cost of sales	10,561	9,255
Gross profit	7,921	7,650
Selling, general and administrative expenses	5,454	5,914
Operating profit	2,467	1,735
Non-operating income		
Interest income	2	0
Commission income	0	0
Compensation income	3	5
Subsidy income	0	3
Insurance claim income	116	0
Other	13	4
Total non-operating income	136	15
Non-operating expenses		
Interest expenses	19	18
Sales discounts	5	3
Foreign exchange losses	76	116
Other	0	0
Total non-operating expenses	101	140
Ordinary profit	2,501	1,610
Extraordinary income		
Gain on sales of non-current assets	1	0
Total extraordinary income	1	0
Extraordinary losses		
Loss on sales of non-current assets	0	0
Loss on retirement of non-current assets	2	15
Loss on valuation of investment securities	_	1,172
Total extraordinary losses	2	1,187
Profit before income taxes	2,499	423
Income taxes - current	653	279
Income taxes - deferred	150	(167)
Total income taxes	803	112
Profit	1,695	311
Profit attributable to non-controlling interests	0	0
Profit attributable to owners of parent	1,695	310

		(Millions of yen)
	Six months ended	Six months ended
	March 31, 2019	March 31, 2020
Profit	1,695	311
Other comprehensive income		
Valuation difference on available-for-sale securities	135	319
Deferred gains or losses on hedges	(23)	-
Foreign currency translation adjustment	(14)	(288)
Remeasurements of defined benefit plans, net of tax	(3)	13
Total other comprehensive income	94	44
Comprehensive income	1,790	355
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	1,790	355
Comprehensive income attributable to non-controlling interests	0	0

Consolidated statements of cash flows

	Six months ended March 31, 2019	(Millions of yen) Six months ended March 31, 2020
Cash flows from operating activities		
Profit before income taxes	2,499	423
Depreciation	930	866
Amortization of goodwill	139	143
Increase (decrease) in allowance for doubtful accounts	(0)	(0
Increase (decrease) in provision for bonuses	(482)	(438
Increase (decrease) in provision for bonuses for directors (and	(9)	(4
other officers)		
Increase (decrease) in retirement benefit liability	31	63
Interest and dividend income	(2)	(1)
Insurance claim income	(116)	(0
Interest expenses	19	18
Foreign exchange losses (gains)	76	100
Loss on retirement of non-current assets	2	15
Loss (gain) on valuation of investment securities	-	1,172
Decrease (increase) in trade receivables	1,207	28
Decrease (increase) in inventories	105	(1,246
Increase (decrease) in trade payables	(1,178)	1,224
Decrease (increase) in long-term advance payments	(64)	-
Other, net	(663)	541
Subtotal	2,495	2,908
Interest and dividends received	2	1
Proceeds from insurance income	116	0
Interest paid	(23)	(19
Income taxes paid	(308)	(447
Net cash provided by (used in) operating activities	2,281	2,442
Cash flows from investing activities	2,201	2,112
Purchase of investment securities	(5,548)	
Purchase of property, plant and equipment	(783)	(1,592
Proceeds from sales of property, plant and equipment	(783)	23
Purchase of intangible assets	(1,499)	(138
Decrease (increase) in long-term advance payments		(138
	(318)	(15
Other, net	(0)	(15
Net cash provided by (used in) investing activities	(8,150)	(1,724
Cash flows from financing activities		
Purchase of treasury shares	-	(0
Proceeds from long-term borrowings	7,000	-
Repayments of long-term borrowings	(210)	(2,420
Dividends paid	(419)	(467
Repayments of lease obligations	(302)	(245
Net cash provided by (used in) financing activities	6,068	(3,133
Effect of exchange rate change on cash and cash equivalents	(15)	(33
Net increase (decrease) in cash and cash equivalents	183	(2,448
Cash and cash equivalents at beginning of period	6,251	8,494
Cash and cash equivalents at end of period	6,435	6,046